Dare Bioscience, Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Effective September 10, 2026, Dare Bioscience amended Section 1.6 of its Third Amended and Restated By-Laws to lower the shareholder quorum requirement from a majority to one-third of voting power for general meetings, while maintaining majority quorum for class-specific votes. This is a standard governance change with no financial impact or counterparties involved.
Why this rating
Routine bylaw amendment reducing operational friction; no financial, strategic, or capital event. Governance procedural change only.
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.